Full Breakdown
Jesy Nelson’s Campaign Highlights Partial Rollout of UK Newborn SMA Screening
6/25/2026, 1:05:09 PM
The Parliamentary Debate Over SMA Screening
On 23 June 2024, Westminster Hall hosted a debate triggered by a petition signed by more than 150,000 people. The petition, launched by former Little Mix singer Jesy Nelson, called for universal newborn screening for spinal muscular atrophy (SMA) across England. The government announced that a screening programme would begin in October 2026—three months earlier than the original January 2027 timetable—but would initially cover only 72 percent of newborns, leaving 28 percent of infants without the test. The debate featured health minister Sharon Hodgson, several MPs, and representatives from Muscular Dystrophy UK and SMA UK.
Background: SMA and Existing Screening Landscape
SMA is a rare genetic disorder that causes rapid muscle wasting; type 1, the most severe form, often leads to death before the second birthday if untreated. Early treatment with gene-therapy drugs such as Zolgensma is life-changing, but benefits depend on diagnosis within weeks of birth. Scotland introduced universal newborn SMA screening in March 2023. In the rest of the UK, screening has been limited to infants with an affected sibling. The UK National Screening Committee (UK NSC) advises a phased rollout to assess effectiveness and NHS cost implications.
Data & Statistics
- Petition signatures: > 150,000 (UK public).
- Planned coverage: 72 % of England’s newborns (? 28 % excluded).
- Excluded areas (first phase): Bristol, Cambridge, Leeds, Liverpool, Oxford, Portsmouth.
- Estimated 2024 SMA births in the UK: 47 infants (SMA UK).
- Carrier frequency: ? 1 in 40 people carry the pathogenic gene.
- Current NHS newborn panel tests 10 rare conditions; SMA is not yet included.
Official Statements & Government Response
Public Health Minister Sharon Hodgson defended the staggered launch, citing insufficient laboratory capacity: six of the thirteen NHS testing labs lack the requisite equipment, and expanding capacity would require time. The UK NSC’s recommendation to evaluate both clinical effectiveness and treatment cost underpins the phased approach. A Department of Health and Social Care spokesperson said a large-scale NHS trial will begin in October 2026, emphasizing that excluded infants are not being used as a “control group” and that the government is exploring options to broaden the programme.
Criticism & Opposition
Nelson described the partial rollout as a “postcode lottery,” arguing that geography should not determine a child’s access to life-saving diagnosis. MP Amanda Martin (Portsmouth North) called the exclusion “alarming,” questioning why babies in her constituency matter less. MP Ruth Jones (Newport West) referenced Ukraine’s wartime implementation of SMA screening as a contrast. Muscular Dystrophy UK welcomed the debate but reiterated its demand for nationwide coverage, stating “No more postcode lottery.”
On-the-Ground Perspective
Nelson detailed daily care for her twins, Ocean Jade and Story Monroe, who require medication every four hours, turning every two hours to prevent choking, and continuous respiratory support. She highlighted that early treatment could have prevented the need for ventilatory machines and allowed the children to achieve typical developmental milestones.
Conflicting Reports & Gaps
Sources differ on the primary barrier to full rollout: Hodgson emphasizes laboratory equipment shortages, while the Department of Health points to gaps in the evidence base on cost-effectiveness. No definitive timeline for extending coverage beyond the initial 72 % has been provided.
Verbatim Quotes
- “I cannot believe we are still debating this.” — Jesy Nelson, Instagram
- “You are basically telling me that if you live in a certain postcode, you're not as important.” — Jesy Nelson, Instagram
- “If it's safe enough for 72% of England to get this tested at birth, then why is it not good enough for the [other] 28%?” — Jesy Nelson, parliamentary debate
- “A spokesperson told PA: "Jesy and other campaigners have made a very powerful case on screening for spinal muscular atrophy, and we have heard that case.” — Department of Health and Social Care spokesperson
- “The babies who aren’t currently included in the evaluation are not being excluded to form a ‘control group’.” — Department of Health and Social Care spokesperson
- “We hope families can feel reassured that progress is being made, with more treatments available for spinal muscular atrophy than ever before – we want to see more children with SMA not just surviving but thriving," the spokesperson added.” — Department of Health and Social Care spokesperson
What’s Next
The October 2026 trial will screen hundreds of thousands of infants across seven NHS laboratories. The government has pledged to assess trial data and consider expanding the programme. Parliamentary committees and health charities are expected to monitor progress and press for a full-nation rollout, aiming to eliminate the current geographic disparity.
